Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eurand has announced that Italian-based Chiesi Farmaceutici has granted Eurand Pharmaceuticals, affiliate of Eurand, an exclusive license to its gastro-resistant, controlled release tablet formulation of the corticosteroid, beclomethasone dipropionate, in the US and Canada.
Subscribe to our email newsletter
The product is currently approved and marketed in the UK, Italy, Spain, and Belgium. Eurand will make an up-front payment and commercial milestone payments to Chiesi Farmaceutici, primarily contingent upon obtaining US regulatory approval for the product. In addition, Eurand will pay royalties on net sales of the product.
The product, marketed in Europe as Clipper(tm) 5mg tablets, is an enteric coated, controlled release formulation of beclomethasone dipropionate, a corticosteroid which is marketed in Europe for use in the treatment of ulcerative colitis.
Eurand’s newly licensed product was developed using a drug delivery system that targets the site of action, or the lower gastrointestinal (GI) tract and provides for a sustained release of drug upon delivery. This technological approach aims to preserve the efficacy of classical corticosteroids while reducing the side effects commonly associated with their use.
Alberto Chiesi, CEO of Chiesi Group, said: “The opportunity to outlicense Clipper to Eurand for the US and Canadian markets is in line with the Group strategy to co-operate with selected partners in order to extend the presence of our products and meet still unmet medical needs.”